ReviewDrugs2016
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Tardive Dyskinesia with Antipsychotic Medication in Children and Adolescents: A Systematic Literature Review.Drug safety · 2024Pooled it
- Pooled it
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.Drug design, development and therapy · 2018Pooled it
- Identifying High-Risk Medications for Drug-Induced Dystonia: A 20-Year Retrospective Real-World Pharmacovigilance Study Based on FAERS.Health science reports · 2026Article
- Article
- The Outcome of Antipsychotics-induced Tardive Syndromes: A Ten-year Follow-up Study.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023Article
- Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States.Psychiatric services (Washington, D.C.) · 2022Article
- Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.Therapeutics and clinical risk management · 2022Review
- Pathophysiology, prognosis and treatment of tardive dyskinesia.Therapeutic advances in psychopharmacology · 2022Review
- Treatable Hyperkinetic Movement Disorders Not to Be Missed.Frontiers in neurology · 2021Review
- Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports.Clinical case reports · 2018Article
- An Update on the Treatment of Chorea.Current treatment options in neurology · 2018Review
- Review
- Functional (psychogenic) stereotypies.Journal of neurology · 2017Article
- Movement disorders and chronic psychosis: Five new things.Neurology. Clinical practice · 2017Article
- Scopolamine alleviates involuntary lingual movements: tardive dyskinesia or dystonia?Neuropsychiatric disease and treatment · 2017Article
- Deutetrabenazine in Tics Associated with Tourette Syndrome.Tremor and other hyperkinetic movements (New York, N.Y.) · 2016Article
- RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.